Northwest Biotherapeutics to Present Next-Generation Dendritic Cell Therapy Advances at Cancer Immunotherapy Conference
核心洞察
Northwest Biotherapeutics' Chief Technical Officer Dr. Marnix Bosch will present on "supercharged" dendritic cells (搜索) with enhanced anti-tumor effects at the Frontiers in Cancer Immunotherapy Conference on June 16.
The company has completed a 331-patient Phase III trial of DCVax-L for glioblastoma (搜索) and submitted a Marketing Authorization Application for commercial approval in the UK.
Northwest Biotherapeutics is developing DCVax-Direct for inoperable solid tumors, having completed a 40-patient Phase I trial with Phase II trials planned for this year.
Northwest Biotherapeutics announced that its Chief Technical Officer Dr. Marnix Bosch will present research on next-generation dendritic cell treatments at the upcoming Frontiers in Cancer Immunotherapy Conference of the New York Academy of Sciences. The presentation, scheduled for Monday, June 16 at 2:50 p.m., will focus on "Next Generation Dendritic Cell Treatments to Improve Anti-Tumor Responses."
Dr. Bosch will address specific factors and combinations of factors that may lead to what the company describes as "supercharged dendritic cells (搜索) with enhanced anti-tumor effects." The presentation slides will be made available on the company's website following the conference.
DCVax Platform Technology
Northwest Biotherapeutics has developed a broad platform technology for DCVax dendritic cell-based vaccines designed to treat cancers more effectively than current treatments. The company's approach aims to avoid the toxicities associated with chemotherapies while maintaining cost-effectiveness.
The company's lead program involves DCVax-L treatment for glioblastoma (搜索) (GBM), described as the most aggressive and lethal form of primary brain cancer and classified as an "orphan disease." Northwest Biotherapeutics has completed a 331-patient Phase III trial of DCVax-L for GBM, with results presented at scientific meetings and published in JAMA Oncology.
Regulatory Progress and Pipeline Development
The company has submitted a Marketing Authorization Application (MAA) for commercial approval of DCVax-L in the UK, which is currently undergoing regulatory review. This represents a significant milestone in the company's efforts to bring its personalized immunotherapy to market.
Beyond glioblastoma (搜索), Northwest Biotherapeutics has developed DCVax-Direct for inoperable solid tumor cancers (搜索). The company completed a 40-patient Phase I trial for this treatment and plans to pursue Phase II trials this year. Additionally, the company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer (搜索) in collaboration with the University of Pennsylvania.
Personalized Immunotherapy Approach
Northwest Biotherapeutics positions itself as a biotechnology company focused on developing personalized immunotherapy products. The DCVax platform represents the company's core technology for creating dendritic cell-based vaccines tailored to individual patients' tumor profiles.
The upcoming presentation at the New York Academy of Sciences conference will provide insights into the company's research on enhancing dendritic cell functionality, potentially advancing the field of cancer immunotherapy through improved cellular responses against tumors.